HIV-1 gag DNA + bupivacaine

A combination investigational product consisting of an HIV-1 gag gene-based plasmid DNA vaccine and the local anesthetic bupivacaine. The vaccine component encodes the full-length or conserved elements of the HIV-1 Gag protein (such as p24CE or p55Gag), designed to elicit cellular immune responses against highly conserved regions of the virus. Bupivacaine is included as a facilitating agent to enhance cellular uptake and stabilization of the plasmid DNA at the injection site. This combination has been evaluated in phase I/II clinical trials for safety, tolerability, and immunogenicity in both people without HIV (as a preventive approach) and people living with well-controlled HIV infection (as an immunotherapeutic strategy). The vaccines are typically administered intramuscularly, sometimes using electroporation for improved delivery[2][3][6]. Developers have included academic groups and companies such as Apollon[1] and Profectus Biosciences[5].

Other names

HIV-1 Gag DNA vaccine with bupivacaineHIV1 Gag DNA vaccine with bupivacaineHIV 1 Gag DNA vaccine with bupivacainep55Gag DNA + bupivacaineHIV-1 Gag p37/p55 DNA vaccine with bupivacaine